Navigation Links
Carbon Nanoneedles For Drug Delivery

A multinational team of researchers based in the UK has found a way to make carbon nanotubes easily cross biological barriers, opening up the potential for a new form of drug delivery// .

UK-based researchers from the School of Pharmacy, University of London, chemically modified carbon nanotubes by adding a range of different functional groups and found that they were able to enter a variety of cell types, including human cancer cells.

Carbon nanotubes have shown potential as a form of drug delivery, but there is a major setback in that they are highly insoluble in their unmodified form.

”This makes them impossible to handle in the biological environment,” Dr Kosta Kostarelos, deputy head of the Centre for Drug Delivery Research and leader of the research group told In-PharmaTechnologist.com.

It is the functionalisation of the carbon nanotubes that allows them to become water soluble, and therefore able to be used in a biological environment with potential applications as a novel drug delivery method.

”The functionalisation of the nanotubes is therefore hugely important.” Dr Kostarelos continued.

The research team found that the functionalised nanotubes were able to easily cross-cell barriers in mammalian, bacterial and fungal cells without causing cell death, and were even able to enter cells under conditions, which would usually hinder this process.

”The nanotubes moved through the cells as individual nanotubes or as small bundles, even under conditions that inhibit [cell absorption]” said Kostarelos.

”Nanotubes capable of acting as cell-penetrating materials will have tremendous advantages. The potential of functionalised carbon nanotubes to act as nanoneedles that pierce plasma membranes and translocate directly into cytoplasm without causing cell damage or death is significant for a variety of biomedical and biotechnology applications.”

While the actual mechanism by which the functionalised nanotubes are taken up by cells is still unclear, the hypothesis that the team is working with is that they simply pierce the cell and move within it.

”What we do know is that whatever functionalised carbon nanotube we used, it was taken up by every different kind of cell we investigated,” said Kostarelos.

”Some types of functionalisation prompted a greater uptake, but it was by no means a prerequisite. All functionalised nanotubes were taken up to a significant extent.”

The research team, with colleagues over in France, have experimented with delivering drugs such as amphotericin B (an anti-fungal treatment) and methotrexate (an anti-cancer drug) using the functionalised carbon nanotubes, but encountered some obstacles with drug release along the way. ”Once you chemically conjugate the drug on the nanotube, the drug is not capable of leaving the nanotube,” Dr Kostarelos explained.

”So we therefore need some kind of reversible association to be able to release the drug intracellularly.”

Technology to tackle this problem does exist, but needs to be modified to address this specific case. The researchers are currently pursuing this line of investigation as part of the next stage of their research.

In February last year the team published results of the first ever-intravenous administration of functionalised carbon nanotubes in vivo, injecting the nanotubes into animals. The results showed that the functionalised nanotubes were excreted very quickly in urine, which is a significant point in favor of their use in drug delivery, as it would alleviate toxicity concerns regarding the nanotubes themselves.

Now, the research team has moved on a step further and has added drugs to the mix rather than the nanotubes on their own. While still in the research stage at present, results are anticipated within the year and according to Dr Kostarelos the results are looking ”ver y promising”.

If the research team's working hypothesis regarding the uptake of functionalised carbon nanotubes is correct, the technique could offer significant advantages over other drug delivery mechanisms currently used.

Traditional delivery methods (using liposomes for example) usually exploit endocytosis, but stop before reaching the cytoplasm leaving other barriers for the drug to fight through. By piercing plasma membranes and heading straight to the cytoplasm, the functionalised carbon nanotube encounters fewer biological barriers and delivers the drug more directly.

The nanotubes also offer a structural advantage in that they are extremely thin but very long, offering a large surface area on which to graft the required drug. This again offers an improvement over liposome drug delivery, and also allows the amount of drug loaded onto the nanotube to be regulated.

Kostarelos observed that developments and improvements in carbon nanotube material are occurring almost daily, and the product itself is therefore likely to become more refined over time. Although difficult to assess the cost of a potential drug delivery product resulting from the technique, Kostarelos noted that there is so many possible applications for carbon nanotubes that they can be produced in bulk very cheaply.

Although functionalisation of the nanotubes would increase the cost slightly, it would still represent ”an economic benefit to pharmaceutical companies, especially compared to liposomes” Kostarelos said.

The functionalised carbon nanotube work is still at a relatively early stage, and the researchers say that they are still defining a framework as far as pharmaceutical development is concerned.

The team is, however, pursuing the line of research and the potential of functionalised carbon nanotubes for drug delivery. Kostarelos told In-PharmaTechnologist that he hopes to have data concerning the efficacy of dr ugs delivered by this novel technique within five years.

Source-Bio-Bi Technology
SRI
'"/>




Related medicine news :

1. Carbon monoxide passes down
2. Research Shows Carbon Monoxide Prevents Inflammations
3. Protein Carbonyl Level Causes Oxidative Protein Damage In Diabetics
4. Absorption Of Carbon Nanotube Measured In Worms Revolutionize Cancer Research
5. Carbon Monoxide May Prevent Pre-Eclampsia
6. Carbon Monoxide May Treat Pre-Eclampsia
7. Benefits of Carbon Monoxide
8. Carbon Monoxide Protects from Multiple Sclerosis
9. Kerala Youth Die of Carbon Monoxide Inhalation
10. Carbon Monoxide Poisoning Claims Another Set Of Victims
11. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology: